Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing the Study
Scope of Report
Methodology
Intended Audience
Information Sources
Analyst Credentials
Related Bcc Reports
Bcc Online Services
Disclaimer
Chapter 2 Summary
Summary Table Global Market for Asthma and COPD Prescription Drugs by Disease, through 2017 ($ Millions)
Summary Figure Global Market for Asthma and COPD Prescription Drugs by Region, 2012 and 2017 (%)
Chapter 3 Overview
Pulmonary Drug Delivery
Pulmonary Conditions and Therapies
Respiratory System
Lung
Particle Size, Toxicity and Drug Deposition
Systemic and Local Therapy
Pulmonary Drug Delivery-Devices
Device Characteristics
Manufacturing Techniques
Asthma
Symptoms of Asthma
Global Prevalence
Chronic Obstructive Pulmonary Disease
Symptoms of COPD
Medication Treatment
Types of Medication Treatments
Classification of Asthma and COPD Medications
Bronchodilators
Quick-Acting Bronchodilators
Two Classes of Long-Term Bronchodilators
Anti-Inflammatory Drugs
Combination Inhaled Corticosteroids and Long-Acting Beta-2 Agonists (Ics/Laba)
Advantages of Ics/Laba
Table 1 Marketed Asthma and COPD Drug Classes
Drug Delivery Methods
Inhaled Drugs
Metered-Dose Inhaler
Pressurized Mdi Devices
Types of Metered-Dose Inhalers
Breath-Activated Inhalers
Types of Breath-Activated Inhalers
Dry Powder Inhalers
Disadvantages of Dpi
Types of Dpi Inhalers
Nebulizers
Usage
Types of Nebulized Drugs
Oral and Injectable Drugs
Oral Drug Types
Injectable Drug Types
Advantages/Disadvantages of Drug Delivery Methods
Drug Development Process
Development of Disease-Modifying Drugs
New Drug Targets
Technical Aspects in the Development of Inhaled Drugs
Intellectual Property Rights
Drug Development
Complex Regulatory Drug Approval Process
Approval Times
Regulatory Issues
Removal of Cfc-Propelled Inhalers
Fda Drug Safety Warnings
Industry Players
Tiers of Competition
Major Drug Manufacturers
Glaxosmithkline
Merck
Boehringer Ingelheim
Table 2 Net Revenues for Top Six Asthma/COPD Product Manufacturers, with Product(S), 2010 and 2011 ($ Millions)
Specialty Pharmaceutical Companies
Teva Pharmaceutical
Chiesi Farmaceutici
Sunovion/Sepracor
Table 3 Net Revenues for Top Specialty Asthma/COPD Manufacturers with Product(S), 2010 and 2011 ($ Millions)
Smaller Companies
Table 4 Net Revenues for Smaller Asthma/COPD Product Manufacturer, with Product, 2010 and 2011 ($ Millions)
Acquisitions and Mergers
Table 5 Acquisitions and Mergers in the Asthma and COPD Market, January 2008 to June 2012 ($ Millions)
Competitive Factors
Six Competitive Factors
Delivery Mode and Convenience
Product Efficacy and Dosage Frequency
Safety
Combination Drugs
Drug Pricing
Sales and Marketing
Significant Trends
Global Aging Population Leads to Increasing Asthma and COPD Prevalence
New Drug Launches Offer Enhanced Treatment Options
Patent Expirations of Major Drugs and Generic Drug Launches Will Change the Market
Table 6 Major Asthma/COPD Drugs That Lose Patent Protection between 2008 and 2024
Market Challenges
Technical- and Market-Specific Expertise Required to Compete in This Therapeutic Area
Filling Unmet Needs
Disease-Modifying Drugs
Superior Efficacy Drugs
Improved Safety Profile Drugs
Improved Drug Delivery Modalities
Improved Quality of Life for Patients
Regional Analysis
The Americas
Demographic Findings
Asthma and Children in the Americas
Loss of Patent Protection
Product Usage
EMRA
Demographic Findings
Asthma and Children
Product Usage
Asia
Demographic Findings
Asthma and Children in Asia
Product Usage
Chapter 4 Disease Overview
Symptom Comparisons
Table 7 Asthma and COPD Symptom Comparisons
Asthma Overview
Asthma in Children
Asthma in Adults
Global Economic Burden of Asthma
Classification of Asthma
Table 8 Classification of Asthma, by Symptoms
Causes and Risk Factors
Diagnosis
Diagnostic Tests
Spirometry
Peak Flow Test
Methacholine Bronchial Challenge Test
Nitric Oxide Test
Skin Or Blood Test
Drug Classes Approved in the Treatment of Asthma and COPD
Table 9 Asthma and COPD Drug Classes
Bronchodilators
Anti-Inflammatory Drugs
Combination Therapies of Bronchodilators and Anti-Inflammatory Drugs
Medication Treatment Algorithms
First Line Therapy
Second Line Therapy
Chronic Obstructive Pulmonary Disease
Classification of COPD
Table 10 Classification of COPD and Asthma
Causes and Risk Factors
Diagnosis
COPD Treatment Methods
Vaccine
Rehabilitation
Oxygen Therapy
Surgery
Medication Treatments
Drug Selection
Regional Statistics
Access to Care
Availability of Treatments
North America
Asthma in the U.S.
Adults and Asthma in the U.S.
Asthma in Canada
Asthma in Central America
Asthma in the Caribbean
Asthma in South America
Table 11 Percent of Selected Populations with Diagnosed Asthma in the Americas (%)
COPD in the U.S.
EMRA
Asthma in EMRA
Scandinavian/Baltic Countries
Asthma in the UK and Ireland
Asthma in Western Europe
Asthma in Eastern Europe
Asthma in Russia
Asthma in the Middle East
Table 12 Percent of Selected Populations with Diagnosed Asthma in the EMRA (%)
COPD in EMRA
COPD in Russia
Asia
Asthma in Asia
Asthma in Central Asia
Asthma in Southern Asia
Asthma in China/Taiwan/Mongolia
Asthma in Northeast Asia
Asthma in Southeast Asia
Asthma in Oceania
Table 13 Percent of Selected Populations with Diagnosed Asthma in Asia
COPD in Asia
Chapter 5 Markets by Drug Class
Table 14 Projected Global Market for Asthma and COPD Drug, by Drug Class, through 2017 ($ Millions)
Bronchodilators
Market Revenues and Forecast
Figure 1 Global Bronchodilator Market, by Type, 2012 and 2017 (%)
Table 15 Projected Global Market for Bronchodilators, through 2017 ($ Millions)
Manufacturers' Market Share for Bronchodilators
Figure 2 Global Market Share for Bronchodilators by Company, 2011 (%)
Short-Acting Beta-2 Agonists
Table 16 Short-Acting Beta-2 Agonists, with Approval and Patent Expiry Dates, 2011
Market Revenues and Forecast
Advantages/Disadvantages
Table 17 Projected Market for Short-Acting Beta-2 Agonist Bronchodilators, through 2017 ($ Millions)
Long-Acting Beta-2 Agonists
Table 18 Long-Acting Beta-2 Agonists, 2011
Market Revenues and Forecast
Table 19 Projected Global Market for Laba Products, through 2017 ($ Millions)
Figure 3 Market Share for Laba Bronchodilators by Company, 2011 (%)
Anticholinergics and Combination Anticholinergics/Saba
Table 20 Anticholinergics and Combination Anticholinergics/Saba by Manufacturer, 2011
Market Revenues and Forecast
Table 21 Projected Global Market for Anticholinergics, through 2017 ($ Millions)
Anti-Inflammatory Drugs
Market Revenues and Forecast
Figure 4 Market Share of Anti-Inflammatory Drugs by Type, 2012 and 2017 (%)
Table 22 Projected Global Market for Anti-Inflammatory Drugs by Type, through 2017 ($ Millions)
Inhaled Corticosteroids
Table 23 Inhaled Corticosteriods, 2011
Figure 5 Market Share of Leading Manufacturers of Inhaled Corticosteriods, 2011 (%)
Competition in the Ics Market
Table 24 Projected Global Market for Inhaled Corticosteroids, through 2017 ($ Millions)
Leukotriene Modifiers
Table 25 Leukotriene Modifiers, 2011
Market Revenues and Forecast
Table 26 Projected Global Market for Leukotriene Modifiers, through 2017 ($ Millions)
Figure 6 Global Market for Leukotriene Modifiers, by Manufacturer, 2012 and 2017 (%)
Pde-4 Inhibitors
Table 27 Projected Global Market for Pde-4 Drugs, through 2017 ($ Millions)
Biological Drugs
Market Revenues and Forecast
Increasing Market for Biological Drugs to Treat Asthma
Table 28 Projected Global Market for Asthma Biological Drugs, through 2017 ($ Millions)
Combination Ics/Laba Drugs
Table 29 Combination Ics/Laba Drugs, 2011
Market Revenues and Forecast
Table 30 Projected Global Market for Combination Ics/Laba Drugs, through 2017 ($ Millions)
Figure 7 Market Share of Manufacturers of Ics/Laba, 2011 (%)
Market Dynamics
Flutiform
Dulera
Relovair
Regional Analysis
Table 31 Projected Revenues From Asthma/COPD Drugs by Region, through 2017 ($ Millions)
The Americas
Table 32 Projected Revenues From Asthma/COPD Drugs in the Americas Region, through 2017 ($ Millions)
Projected Use of Asthma/COPD Drugs, by Americas' Regions
Table 33 Projected Use of Asthma/COPD Drugs in the Americas' Region, through 2017 ($ Millions)
Figure 8 Market Percent of Asthma/COPD Drugs in the Americas Region, 2012 and 2017 (%)
EMRA
Table 34 Projected Revenues From Asthma/COPD Drugs in the EMRA, through 2017 ($ Millions)
Table 35 Projected Use of Asthma/COPD Drugs in the EMRA Region, through 2017 ($ Millions)
Figure 9 Market Percent of Asthma/COPD Drugs in the EMRA, 2012 and 2017 (%)
Asia
Table 36 Projected Revenues From Asthma/COPD Drugs in the Asian Region, through 2017 ($ Millions)
Table 37 Projected Use of Asthma/COPD Drugs, by Region in Asia, through 2017 ($ Millions)
Figure 10 Market Percentage of Asthma/COPD Drugs, by Region in Asia, 2012 and 2017 (%)
Chapter 6 Markets by Disease
Figure 11 Global Market for Asthma and COPD Prescription Drugs by Disease, 2011 (%)
Asthma Drugs
Market Revenues for Asthma Drugs
Market Shares, by Company
Figure 12 Market Shares of Leading Manufacturers of Asthma Drugs, 2011 (%)
New Branded Asthma Drugs Launches
Generic Drug Launches
Table 38 Projected Global Market for Asthma Prescription Drugs, through 2017 ($ Millions)
Chronic Obstructive Pulmonary Disease
Figure 13 Market Shares of Leading Manufacturers of COPD Drugs, 2011 (%)
Table 39 Projected Global Market for COPD Prescription Drugs, through 2017 ($ Millions)
Branded COPD Product Launches
Combination Asthma/COPD Drugs
Table 40 Projected Global Market for Combination Asthma/COPD Drugs, through 2017 ($ Millions)
Figure 14 Market Shares of Leading Manufacturers of Combination Asthma/COPD Drugs, 2011 (%)
Table 41 Projected Global Market for Combination Asthma/COPD Prescription Drugs, through 2017 ($ Millions)
Chapter 7 Emerging Trends and Product Pipeline Review
The "Asthma Gene"
Oral Drugs for Asthma
Leukotriene Oral Drugs
Masitinib
Oral Antifungal Treatment for Severe Asthma
Disease Modifying Drugs
Asthma Formulations
COPD Formulations
Boehringer Ingelheim
Forest Laboratories/Amirall Sa
Elevation Pharmaceuticals
Pearl Therapeutics
Novel Biologics
Amg 157
Amg 176
Mepolizumab
Ultra Long-Acting Muscarinic Antagonists
Ultra Long-Acting B2 Agonists (Ultra-Laba)
Lama and Laba Combination Drugs
Anti-Inflammatory Drugs
Anti-Protease
Chemokine Antagonists
Ppar Agonists
Asthma/COPD Drug Development, by Company
Table 42 Asthma/COPD Products Under Development, by Company, 2012
Asthma Devices
Chapter 8 Approved Drugs and Patent Review
Table 43 Approved Drugs to Treat Asthma and COPD, 1996 through 2011
Table 44 Drugs Seeking Approval to Treat Asthma and COPD 2012 through 2013
Patent Review
Table 45 Asthma/COPD Treatment Patents, by Company, Disease, Patent Number, Year Filed, 2011 through 2012
Figure 15 Percent of Reviewed Patents for Asthma, COPD, and Combination Use, January 2011 to May 2012 (%)
Table 46 Asthma/COPD Treatment Patents, by Number, Company, Description, and Date Issued, 2011 through 2012
Table 47 Asthma/COPD Drug Treatment Patents Issued between January 2011 and May 2012, by Company
Figure 16 Asthma/COPD Patents, by Country, 2011 through 2012 (%)
Chapter 9 Company Profiles
Actient Pharmaceuticals
Aerovance, Inc.
Almirall, S.A.
Amgen Inc.
Aptar Pharma
Argenta Discovery, Ltd.
Astrazeneca
Astrazeneca Pharmaceuticals, Lp
Boehringer Ingelheim Gmbh
Chiesi Farmaceutici Spa
Cornerstone Therapeutics
Cytos Biotechnology Ag
Dey Pharma (Mylan Specialty L.P.)
Forest Laboratories, Inc.
Genentech, Inc. (Roche)
Glaxo Wellcome U.K., Ltd.
Glaxosmithkline U.S.
Medicinova
Medicis Pharmaceutical
Medimmune
Merck & Co., Inc.
Novartis Pharma
Novartis Corporation
Novartis Pharmaceuticals Corporation
Nycomed International (Takeda International)
Osiris Therapeutics, Inc.
Pfizer, Inc.
Sepracor, Inc. (Sunovion)
Skyepharma Plc
Teva Pharmaceutical Industries, Ltd.
Teva Pharmaceuticals Usa
Theravance
Relovair
Lama/Laba (Gsk573719/Vilantrol)
Bifunctional Muscarinic Antagonist-Beta2 Agonist Program
Inhaled Long-Acting Muscarinic Antagonist (Lama)
Topigen Pharmaceuticals, Inc. (Pharmaxis Ltd)
Vectura Group Plc
List of Tables
Summary Table Global Market for Asthma and COPD Prescription Drugs by Disease, through 2017 ($ Millions)
Table 1 Marketed Asthma and COPD Drug Classes
Table 2 Net Revenues for Top Six Asthma/COPD Product Manufacturers, with Product(S), 2010 and 2011 ($ Millions)
Table 3 Net Revenues for Top Specialty Asthma/COPD Manufacturers with Product(S), 2010 and 2011 ($ Millions)
Table 4 Net Revenues for Smaller Asthma/COPD Product Manufacturer, with Product, 2010 and 2011 ($ Millions)
Table 5 Acquisitions and Mergers in the Asthma and COPD Market, January 2008 to June 2012 ($ Millions)
Table 6 Major Asthma/COPD Drugs That Lose Patent Protection between 2008 and 2024
Table 7 Asthma and COPD Symptom Comparisons
Table 8 Classification of Asthma, by Symptoms
Table 9 Asthma and COPD Drug Classes
Table 10 Classification of COPD and Asthma
Table 11 Percent of Selected Populations with Diagnosed Asthma in the Americas (%)
Table 12 Percent of Selected Populations with Diagnosed Asthma in the EMRA (%)
Table 13 Percent of Selected Populations with Diagnosed Asthma in Asia
Table 14 Projected Global Market for Asthma and COPD Drug, by Drug Class, through 2017 ($ Millions)
Table 15 Projected Global Market for Bronchodilators, through 2017 ($ Millions)
Table 16 Short-Acting Beta-2 Agonists, with Approval and Patent Expiry Dates, 2011
Table 17 Projected Market for Short-Acting Beta-2 Agonist Bronchodilators, through 2017 ($ Millions)
Table 18 Long-Acting Beta-2 Agonists, 2011
Table 19 Projected Global Market for Laba Products, through 2017 ($ Millions)
Table 20 Anticholinergics and Combination Anticholinergics/Saba by Manufacturer, 2011
Table 21 Projected Global Market for Anticholinergics, through 2017 ($ Millions)
Table 22 Projected Global Market for Anti-Inflammatory Drugs by Type, through 2017 ($ Millions)
Table 23 Inhaled Corticosteriods, 2011
Table 24 Projected Global Market for Inhaled Corticosteroids, through 2017 ($ Millions)
Table 25 Leukotriene Modifiers, 2011
Table 26 Projected Global Market for Leukotriene Modifiers, through 2017 ($ Millions)
Table 27 Projected Global Market for Pde-4 Drugs, through 2017 ($ Millions)
Table 28 Projected Global Market for Asthma Biological Drugs, through 2017 ($ Millions)
Table 29 Combination Ics/Laba Drugs, 2011
Table 30 Projected Global Market for Combination Ics/Laba Drugs, through 2017 ($ Millions)
Table 31 Projected Revenues From Asthma/COPD Drugs by Region, through 2017 ($ Millions)
Table 32 Projected Revenues From Asthma/COPD Drugs in the Americas Region, through 2017 ($ Millions)
Table 33 Projected Use of Asthma/COPD Drugs in the Americas' Region, through 2017 ($ Millions)
Table 34 Projected Revenues From Asthma/COPD Drugs in the EMRA, through 2017 ($ Millions)
Table 35 Projected Use of Asthma/COPD Drugs in the EMRA Region, through 2017 ($ Millions)
Table 36 Projected Revenues From Asthma/COPD Drugs in the Asian Region, through 2017 ($ Millions)
Table 37 Projected Use of Asthma/COPD Drugs, by Region in Asia, through 2017 ($ Millions)
Table 38 Projected Global Market for Asthma Prescription Drugs, through 2017 ($ Millions)
Table 39 Projected Global Market for COPD Prescription Drugs, through 2017 ($ Millions)
Table 40 Projected Global Market for Combination Asthma/COPD Drugs, through 2017 ($ Millions)
Table 41 Projected Global Market for Combination Asthma/COPD Prescription Drugs, through 2017 ($ Millions)
Table 42 Asthma/COPD Products Under Development, by Company, 2012
Table 43 Approved Drugs to Treat Asthma and COPD, 1996 through 2011
Table 44 Drugs Seeking Approval to Treat Asthma and COPD 2012 through 2013
Table 45 Asthma/COPD Treatment Patents, by Company, Disease, Patent Number, Year Filed, 2011 through 2012
Table 46 Asthma/COPD Treatment Patents, by Number, Company, Description, and Date Issued, 2011 through 2012
Table 47 Asthma/COPD Drug Treatment Patents Issued between January 2011 and May 2012, by Company
List of Figures
Summary Figure Global Market for Asthma and COPD Prescription Drugs by Region, 2012 and 2017 (%)
Figure 1 Global Bronchodilator Market, by Type, 2012 and 2017 (%)
Figure 2 Global Market Share for Bronchodilators by Company, 2011 (%)
Figure 3 Market Share for Laba Bronchodilators by Company, 2011 (%)
Figure 4 Market Share of Anti-Inflammatory Drugs by Type, 2012 and 2017 (%)
Figure 5 Market Share of Leading Manufacturers of Inhaled Corticosteriods, 2011 (%)
Figure 6 Global Market for Leukotriene Modifiers, by Manufacturer, 2012 and 2017 (%)
Figure 7 Market Share of Manufacturers of Ics/Laba, 2011 (%)
Figure 8 Market Percent of Asthma/COPD Drugs in the Americas Region, 2012 and 2017 (%)
Figure 9 Market Percent of Asthma/COPD Drugs in the EMRA, 2012 and 2017 (%)
Figure 10 Market Percentage of Asthma/COPD Drugs, by Region in Asia, 2012 and 2017 (%)
Figure 11 Global Market for Asthma and COPD Prescription Drugs by Disease, 2011 (%)
Figure 12 Market Shares of Leading Manufacturers of Asthma Drugs, 2011 (%)
Figure 13 Market Shares of Leading Manufacturers of COPD Drugs, 2011 (%)
Figure 14 Market Shares of Leading Manufacturers of Combination Asthma/COPD Drugs, 2011 (%)
Figure 15 Percent of Reviewed Patents for Asthma, COPD, and Combination Use, January 2011 to May 2012 (%)
Figure 16 Asthma/COPD Patents, by Country, 2011 through 2012 (%)
